METHOD FOR POTENTIATING PRIMARY DRUGS IN TREATING MULTIDRUG RESISTANT CELLS

Abstract: The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, apparently by reversing or inhibiting the glycoprotein "pumps" associated with such cells.

Description: METHOD FOR POTENTIATING PRIMARY DRUGS IN TREATING MULTIDRUG RESISTANT CELLS BACKGROUND OF THE INVENTION Multidrug resistance is a phenomenon which has been observed in cancer and in a number of parasitic diseases such as malaria, tuberculosis, Enta oeba histolytica (amoebic dysentery) , Trypanosoma (African sleeping sickness) , Leishmania and AIDS pneumonia. A number of diverse drugs have been found effective against such diseases. However in many cases, the initial success of physicians in treating the disease is followed by total failure. Drugs which worked initially become totally ineffective after a period of time. An initial period of remission is often followed by a period of frustration during which nothing seems to be effective against the disease. Death becomes inevitable. Such multidrug resistance in cancer cells has been associated with an increase in the drug resistant cell of the presence of 150,000 to 170,000 molecular weight glycoproteins. Such P150-170 Kd glycoproteins act as a drug exit pump, to pump disease fighting drugs out of the infected or infecting cells which the drugs are supposed to kill. This glycoprotein pump phenomenon in cancer cells has been reported in a March 1989 Scientific American article by Kartner and Ling. (No concession is made that this publication is prior art as to subject matter contained in the parent applications.) The presence of a very similar glycoprotein pump in drug resistant malaria has also been discovered by the inventor. It has been reported by Rothenberg and Ling that multidrug resistance in cancer can be reversed by using hydrophobic molecules with two planar aromatic rings and a tertiary basic nitrogen atom with a positive charge at physiologic pH. Journal of the National Cancer Institute. Vol. 81, No. 12, June 21, 1989, on page 907. (No concession is made that this publication is prior art as to subject matter contained in the parent applications.) A representative compound of this class, and indeed apparently a member of this class which has actually been the subject of much experimental work is the drug verapamil, whose structural formula is shown below: Verapamil is a calcium channel blocker. Other researchers have claimed that calcium channel blockers are effective against malaria. However while such results may be substantiatable in vitro, they have little practical value as clinical treatments in vivo. While calcium channel blockers are therapeutic in the treatment of hypertension at moderate levels, they are toxic at levels high enough to effect MDR reversal. Another technique for MDR reversal in cancer which is of laboratory interest but which has no practical applicability involves inducing point mutations of the energy related ATP binding sites in the glycoprotein. Such point mutations result in an almost complete loss of MDR activity, according to Rothenberg and Ling, supra. While such in vitro work is important, it lacks in vivo clinical applicability. Shiraishi et al. disclose in vitro work on the use of cepharanthine to treat multidrug resistance in cancer. Isotetrandrine, tetrandrine, fangchinoline and berbamine are said to show similar effects in cancer. Anti-tumor effects of tetrandrine have also been mentioned. Heretofore, the phenomenon of multidrug resistance in such disease cells has been attributed to the presence of naturally occurring P150-170 Kd glycoproteins in the disease cells. It is believed that when the disease colony is exposed to treatment, the cells with the glycoprotein, or with a higher percentage thereof, survive the initial treatment while cells without glycoprotein, or with a lesser concentration thereof, do not. The surviving remnant then reproduces and eventually creates a colony which is substantially if not totally resistant to treatment with any drug. A recent publication in the Proceedings of the National Academy of Science, reveals that multidrug resistance can also be caused by viral infection. "A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells," Proc. Natl. Acad. Sci. USA. Ira Pastan et al., Vol. 85, pages 4486-4490, June 1988, Medical Sciences. The authors inserted a full-length cDNA for the human multidrug resistance gene (MDR1) into a retroviral vector. They were able to infect cells with this virus so that the cell expressed P-glycoprotein and rendered the cell multidrug resistant. This experimental work raises the specter of multidrug resistant infection through accidental release of such manufactured retrovirus. Perhaps more significantly, it suggests the possible natural occurrence of retrovirus carrying such cDNA. The implications of these possibilities are that diseases normally treatable with drugs initially, including cancers, may become untreatable ab initio due to infection with such multidrug resistance carrying virus. Such virus could through natural or artificial means infect body cells which may later become cancerous, or could infect the cells of parasitic diseases such as malaria, tuberculosis, AIDS pneumonia, African sleeping sickness and other such diseases. The presence of sizable colonies of such multidrug resistant disease cells would render the diseases and cancers particularly aggressive and virulent and very possibly baffling to an unsuspecting physician. Researchers throughout the world continue to press for techniques for reversing multidrug resistance. A successful clinical technique for reversing multidrug resistance will be one of the most important breakthroughs in the fight against cancer, malaria. tuberculosis and other diseases exhibiting the multidrug resistance phenomenon. SUMMARY OF THE INVENTION In the present invention it has been surprisingly found that methoxadiantifoline, tetrandrine and certain of its derivatives act not only to reverse multidrug resistance but also to potentiate the effectiveness of a primary drug against a drug resistant cell. The method of the present invention appears to reverse or inhibit the glycoprotein pump of a multidrug resistant cell so that such a resistant cell actually accepts a greater concentration of drug than a so-called drug resistant cell. These surprising and unexpected results, as well as other objects, advantages and features of the present invention will be more fully understood and appreciated by reference to the Description of the Preferred Embodiment and appended drawings. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a graph comparing different concentrations of doxorubicin when used against drug resistant DX20, alone and in combination with different "concentrations of tetrandrine, and when used against drug sensitive parent MES-SA cells; Figure 2 is a graph comparing different concentrations of vinσristine when used against drug resistant DX20, alone and in combination with different concentrations of tetrandrine, and when used against drug sensitive parent MES-SA cells; Figure 3 is a graph comparing different concentrations of vinblastine when used against drug resistant DX20, alone and in combination with different concentrations of tetrandrine, and when used against drug sensitive parent MES-SA cells; Figure 4 is a graph comparing different concentrations of doxorubicin when used against drug resistant A2780AD10, alone and in combination with different concentrations of tetrandrine, and when used against drug sensitive parent A2780 cells; Figure 5 is a graph comparing different, concentrations of doxorubicin when used against drug resistant DX20, alone and ' in combination with different concentrations of tetrandrine, and when used against drug sensitive parent MES-SA cells; Figure 6 is a graph demonstrating the effect doxorubicin and tetrandrine used as a single agent have on tumor size; Figure 7 is an isobologram showing the effectiveness of tetrandrine and chloroquine at 50% inhibition concentrations against sensitive and resistant malarial strains; Figure 8 is an isobologram showing the effectiveness of tetrandrine and qinghaosu at 50% inhibition concentrations against sensitive and resistant malarial strain. DESCRIPTION OF THE PREFERRED EMBODIMENT In the preferred embodiment, the tetrandrine like compounds of the present invention have the following where R and R ' are the same or different shortchained carbon based ligand including without limitation, CH_, C0 2 CH 3 or H; and R_ is CH_ ; and 3 is CH 3 or hydrogen; and has the "S" isomeric configuration at the C-1 1 chiral carbon location. The tetrandrine family of compounds as a whole includes tetrandrine, isotetrandrine, hernandezine, berba ine, pycnamine, phaeanthine, oba egine and fangchinoline, which list is not intended to be exhaustive. In all of these examples, R. and R.^ constitute the methyl group. Variation within the group occurs in that R_ and R- may constitute either a methyl group or hydrogen, and the isomeric configuration of the compounds at the C-1 and C-1' chiral carbon positions is either R (rectus) or S (sinister) . The rules for R and S configuration can be found in Morrison and Boyd, "Organic Chemistry," 4th Edition, copyright 1983 by Allyn and Bacon, at pages 138-141. In addition, hernandezine includes a methoxy group at the C-5 position, a substitution which does not appear to be significant in the operability of the compound in the present invention. The specific manner in which these exemplary family members vary is set forth in Table VII below, wherein these family members are compared to two nonfamily members for activity against drug sensitive and drug resistant strains of P. falciparum malaria. Not all members of the tetrandrine family of compounds operate to enhance or potentiate the activity of a primary drug against a multidrug resistant cell. Only those members of the family having the specific configuration outlined above are operable in this manner. Of the eight representative members of the family above, only tetrandrine, isotetrandrine, hernandezine and berbamine act to potentiate the primary drug against ' multidrug resistant cells. In addition to these specific members of the tetrandrine family, it has been found that methoxadiantifoline also potentiates the effectiveness of a primary drug against a multidrug resistant cell. These compounds actually make the drug resistant cell more sensitive to the inhibitory action of a drug than is the so-called drug sensitive cell. At present, the only logical explanation for this result is that the method of the present invention actually involves reversing the glycoprotein pumps which are found in greater abundance on drug resistant cells. Another explanation is that multidrug resistant cells are actually more sensitive than drug sensitive cells to the primary toxic drug but this cannot be seen until the exit pump is inhibited. Thus the glycoprotein pump mechanism which originally made the cell multidrug resistant to drug inhibition actually works against the cell in the present invention to make the cell more sensitive to drug inhibition. A specific in vivo dosage for each of the various compounds used in the present invention has not been established. However, such dosage can be established through routine clinical experimentation by referencing the concentrations at which the various compounds have exhibited 50% inhibition as set forth in Tables III through VII herein. These concentrations have been from about .1 to about 3 micro molar. Such concentrations can be achieved in vivo by administering dosages of from about 100 to about 300 mg/day. It is known that at these concentrations, tetrandrine is substantially nontoxic. The preferred method for administering the drug is orally, though other methods such as injection may be used. In the treatment of various cancers whose cells are multi-drug resistant, a member of the tetrandrine family as described above, or mixtures thereof, is administered in conjunction with primary drugs known to have effectiveness against particular cancers. The following are anti-cancer drugs which are pumped by the multidrug resistance mechanism: doxorubicin, vinblastine, vincristine, adriamycin, mythramycin, actinomycin D, colchicine, daunomycin, mitoxantrone, VP-16 (podophyllotoxin) . The effectiveness of tetrandrine in potentiating anticancer drugs in multidrug resistant cancer cells was determined with respect to three drug combinations: tetrandrine and doxorubicin; tetrandrine and vincristine; and tetrandrine and vinblastine. These combinations were investigated in the following multiple drug resistant human cancer cell lines: MES-SA/DX20 (the parent and doxorubicin-resistant cell lines from uterine leiomyosarσo a) and A2780/A2780AD10 (the parent and multiple drug resistant cell lines from an individual with ovarian cancer) . The MES-SA/DX20 cell line was established according to the development methods of Sikic et al. , Resistance to Antineoplastic Drugs. Chap. 3, CRC Press, Ed. David Kessel, pp. 37-47 (1989) . In vitro drug sensitivity testing consisted of two assay models, the modified MTT assay (Moss ann, J. Immunolog. Methods, Vol. 65, pp. 55-63, 1983) and the clonogenic assay. In addition to this, the combinations were investigated in vitro in nude mice bearing the DX20 cell line. The MTT assay was chosen because of its practical advantages in large-scale screening. The assay involved cellular conversion of tetrazolium salt to a colored formazan serving as a measurement of cell viability. In a given experiment, culture media, 50 microliters, containing 8,000 - 25,000 cells, depending on the proliferation rate of the cell line, was pipetted into each well of several 96-well microtiter plates. The cells were allowed to attach overnight. 100 microliters of d-Tetrandrine-(S) solution, at a concentration below that established as an independent 5Q was then added to each well of the plates. The cytotoxic drug, also at a concentration below that previously established as an IC 50 , was then added at decreasing concentrations by 25% to several half plate sections. The cells were allowed to grow for 72 hours. 100 microliters of media was then removed and 25 microliters of 5 mg/ml MTT (Sigma, St. Louis, MO) in phosphate buffered saline was added to each well. The plates were kept in an incubator at 37 β C and 5% C0 2 . After 2-3 hours of incubation, the extraction buffer containing 20% w/v SDS and 50% DMF was added and the plates again incubated overnight. The plates were read at a test wavelength of 570 nm on a multiwell spectrophotometer (Model MR 700, Dynatech Laboratories, Alexandria, VA) . Each drug combination was tested in triplicate. Percent survival was defined as percent of optical density (OD) of the drug-treated wells to that of the control detected by the spectrophotometer. Figures 1, 4 and 5 demonstrate that doxorubicin- resistance can be either partially or completely reversed with the addition of tetrandrine. Figure 1 demonstrates that when tetrandrine at 1.0 x 10 —6 M is combined with doxorubicin at 1.2 x lθ "8 M there is a dramatic shift to the left. This shift demonstrates that the DX20 doxorubicin- resistant cell line becomes more sensitive to doxorubicin than the parent (MES) cell line. The calculated IC_._ values also demonstrate that if the tetrandrine dose is increased from 2 x 10 -7 to 1 x 10-6 -7 the doxorubicin dose can be decreased from 6.6 x 10 to 3.4 x 10 —8. Figures 2 and 3 demonstrate that vincristine-resistance and vinblastine resistance can be either partially or completely reversed with the addition of tetrandrine as well. The second assay model used, colony formation assay, consisted of 1000-1500 cells, again depending on the proliferation rate of the cell line being added to each well of 24 well microtiter plates in 500 microliters of culture media. The cells were allowed to attach overnight. As in the MTT, culture media containing d-Tetrandrine-(S) and also a cytotoxic drug were added at concentrations below those previously established as independent IC 5Q values. The plates were incubated for a total of 7 days before being fixed in 2.5% glutaraldehyde and stained with crystal violet. Quantitations of colony growth were assessed using an ultrasensitive imaging device (LCVS-5, I.P.S., Pittsburgh, PA). A colony is defined as any cluster of 30 or more cells. Percent inhibition was directly measured against control plates containing no drugs. Figure 5 suggests also that doxorubicin-resistance can be either partially or completely reversed with the addition of tetrandrine. In addition, the effects of d-Tetrandrine-(S) plus doxorubicin in Nu/Nu athymic mice inoculated with DX20 sarcoma cells, 76 x resistant when compared to the parent MES-SA cells were examined. Four cohorts of nude animals bearing the DX20 tumor were treated in groups of 5 (control, doxorubicin, tetrandrine, and doxorubicin + tetrandrine) . Initial data was gathered by monitoring tumor growth, comparing visible retardation in experimental groups receiving 2 cycles of d-Tetrandrine-(S) and doxorubicin over those receiving either d-Tetrandrine-(S) or doxorubicin alone in comparable amounts. (See Fig. 6). Tumor size was calculated using the formula (4 Pi/3) X * Y * 2Z. Additional analysis showed that when given in 3 intraperitoneal injections over 120 hours, 150 g/kg total, 54 micrograms/gram tissue d-Tetrandrine-(S) could be detected at the tumor. An L.D. 5Q dose of 260 mg/kg was also calculated by administering single escalating injections of the compound. Tables I & II and Figure 6 give the actual measurements. TABLE I Tumor Measurements on Day 7 Prior to Treatment Length Width Depth TABLE II Tumor Measurements n a The study was done with 3-4 week old male balb-C nude mice. The animals were injected with DX20 1 x 10 cells. The animals were treated with tetrandrine on days 6, 8, 10 (1.5 mg, 1 mg, and 0.5 mg) . The mice were given doxorubicin 5.5 mg/kg on day 12. The effectiveness of tetrandrine in potentiating anti alarial drugs in multidrug resistant parasitic malarial cells was determined by comparing the antimalarial action of tetrandrine and chloroquine alone and in combination against a P. falciparum malarial strain which is sensitive to chloroquine and another which is resistant to chloroquine. A similar study was conducted using tetrandrine and qinghaosu. Chloroquine and qinghaosu are commonly used antimalarial drugs. The dose (IC 5Q ) of each drug or each drug combination required to effect a 50% inhibition in the malarial activity of each strain was determined by establishing a dose response curve for each. FCMSUl/Sudan strain and cloned Indochina (W-2) strain of P. falciparum were used. The former is sensitive to chloroquine and the latter is resistant to chloroquine. The two strains of the parasite were cultured according to the candle jar method of Trager and Jensen, Science. Vol. 193, pages 673-675 (1976) . In a given experiment, four-day-old Petri dish cultures (approximately 10% parasite ia) were diluted with medium containing an amount of noninfected type A human erythrocytes to obtain a culture with a final hematocrit of 1.5% and parasitemia of 0.5-1.0%. The resulting culture was ready for addition to miσrotitration plates with ninety-six flat-bottom wells. The testing procedure used was similar to that described by Desjardins et al. in "Antimicrobial Agents and Chemotherapy," Vol. 16, pages 710-718 (1979). Briefly, the final volume added to each of the ninety-six well microti- tration plates was 250 microliters and consisted of 25 microliters of complete medium with or without the primary drug (chloroquine or qinghaosu) , 175 microliters of either the parasitized culture or a nonparasitized human -12- erythrocyte control, and 25 microliters of complete medium with or without tetrandrine. 25 microliters radioactive (0.5 microCi) [2,8- 3 H] adenosine. The microtitration plates were incubated in a candle jar for an additional 18 hours, at 37' C. As the malaria parasite grows 3 H-adenosine is metabolized and incorporates into polymeric RNA and DNA. The labeled polymers are trapped on glass fiber filters and unincorporated material is washed away. In the absence of drug there is 100% incorporation of the labeled material. When drugs interfere (directly or indirectly) , an inhibitory dose of 50% (IC 50 ) can be calculated. The experiments were repeated three times except where noted. Statistical analysis was done using Student's T-test for significance. Van Dyke et al. "Exp. Parasitol," Vol. 64, pages 418-423 (1987) . When tetrandrine is added to chloroquine, it supplements and potentiates the antimalarial activity. When tetrandrine is added to qinghaosu or chloroquine, it provides long-acting and synergistic activity to qinghaosu or chloroquine. This can be seen in Tables III-VI and in figures 7 & 8. Remarkably, when 3.0 miσromolar tetrandrine is added to 0.1 miσromolar chloroquine, the IC_ 0 of chloroquine can be lowered 3-Fold. TABLE III tC 5 o (nM)OFTTANDCQFOR EACH DRUG ALONEANDINCOMBINATION' SINGLE DRUG DRUG COMBINATION* MALAΠIA* TT CO TT(I.OuM) TT(2.0uM) T O.Ou ) C ' O(0.3uM} CQ(0.2uM) CQ(Q.1 uM) S STRAIN 49 β ..χ93.7 2 β .7χ3. β S4.9*7.1(TT) 114.1j.23.0(TT) 223.3 4 3β.6(TT) 16.5*2.1(00} 11. t 2.3(00) 7 .4 ± 1.3(00) R STRAIN 197.5_.24.7 165.8*4.9 79.St13.7CTT ) 7β.5t16.1(TT) 1 2 .6± 9 8(TT) 23.8*4.1(00) I.O±. l.β(CO) 4.2± O j(00) • . _• d-l- In t_« l.bl* tt>ov« ■ . • tht rntin vϋu»» * S.O (nM) Irgm l ι -» • _p*rlm«_ «_e«pt htri noltd. " R»lloι of TT/CO In th» drug eomblnillont »r« 10:3. ~ Q \ and 30:1 f »ιp«c l lv« l y. •*■ S and H iirtlnt '«ort ιtni CO.*«n«ιιlvf (FCMSUI'Swdin) ind rail t linl ( w2 ) ilrtln of P. 'i - towrurη rt ipvelivtly When the inhibiting activity of two drugs, e.g., A and B are compared, the middle point of the dose response curve is usually chosen as the basis for comparison. This point is known as the inhibitory dose that occurs at the point of 50% inhibition of the response to be measured (inhibitory concentration at 50% inhibitory response = Ic so^ * An isobologram is developed by comparing the IC 5Q of one drug against the other, i.e., drug A against drug B. We start by putting the IC_ 0 of drug B at the top of the y axis marked 1.0. The IC 5 _ of drug A is placed at the position 1.0 on the x axis. The combinations of drug A and drug B are mixed and tested that are below IC_ 0 of either drug and the points are located on the graph. If the two drugs are additive, there is a straight line between the Y-, 0 (drug B) and Y Q X^ (drug A) . If the line or curve bends below the straight line, the drugs are synergistic or potentiating. If the line bends above the straight line, the two drugs are antagonistic. -14- TABLE IV IC 50 (nM) OF TT AND QHS FOR EACH DRUG ALONE AND IN COMBINATION * SINGLE DRUG DRUG COMBINATION" MALARIA" TT OHS TT(1.0uM) TT(2.0uM) TT(3.0uM) QHS(0.3uM) QHS(0.2uM) OHS(0.1 uM) S STRAIN 410.2*69.0 36.7*4.7 71.9*β.9fTT) 113.S*6.3(TT) 219.5±35.5CTT) 21.6*2.7(OHS), 11.4±0.β(OHS) 7.3±1.2(QHS) R STRAIN 205.6*49.8 47.8*14.5 59.6*13.7(TT) 71.8±13.β{7T) 136.9*41.6fTT) 17.9*4.1(OHS) 7.2*1.4(OHS)" 4.6* 1.4(OHS) * Tha data In lha labla abova ara lha maan valuta * S.O (nM ) trom Ihraa experiments except whara nolad. ** Ralloa ol TT/OHS In the drug combinations ara 10:3. 10:1 and 30:1 respectively. *" S and R alralna rapretenl CO .analllve (FCMSUt/Suden) and realtlent (VY 2) •Iraln ol P.falcl.a um respectively. -15- TABLE V EFFECT OF COMBINATION OF TETRANDRINE AND CHLOROQUINE ON P.FALCIPARUM SFIC* MALARIA" TRIAL 1.0 uM TT 2.0 uM TT 3.0 υM TT 0.3 υM CQ 0.2 υM CQ 0.1 UM CQ S STRAIN 0.77 0.66 0.73 2 0.64 0.77 0.70 3 0.78 0.55 0.75 MEAN * S.D 0.73 10.06 0.66 ± 0.09 0.73 ± 0.02 R STRAIN 1 0.60 0.45 0.74 2 0.68 0.63 0.7β 3 0.36 0.30 0.50 EAN * S.D 0.5,5 * 0.14 0.40 * 0.14 0.67 ± 0.12 ' SFIC represents sum ol fractional Inhibitory concentration as described by Berenbaυm (11), SFIC Is equal to one In cases of additive effects of the drugs, higher tr> . n one In cases of antagonism and lower than one In ' sγnerglstlc acti ~ :<. " S and R strain: c. sroqulne sensitive (FCMSUl/Sudon) and resistant (w2) strain of EiliCJpiCUJTL TABLE VI EFFECT OF COMBINATION OF TETRANDRINE AND QINGHAOSU ON P.FALCIPARUM SFIC* MALARIA" TRIAL 1.0 uM TT 2.0 υM TT 3.0 uM TT 0.3 υM QHS 0.2 uM QHS 0.1 UM QHS S STRAIN 1 0.66 2 0.49 3 0.62 MEAN * S.D 0.60 A 0.08 R STRAIN 1 0.48 2 0.72 3 0.40 MEAN * S.D 0.52 * 0.14 ' SFIC represents sum of fractional inhibitory concentration a s described by Berenbaum (1 1), SFIC Is equal to one in cases of additive effects of Ihe drugs, higher than one In cases of antagonism and lower than one In syπerglstlc action. ** S and R strain: chloroquine sensitive (FCMSU l/Sudon) end roslslonl (VV2) strains of P.lalclparum. In an attempt to explain this surprising result, tetrandrine and various of its derivatives and several nontetrandrine derivatives were tested for their individual effectiveness against a chloroquine sensitive and a chloroquine resistant strain of P falciparum malaria. The test procedure was basically the same as outlined above. The nonfa ily members were cycleanine, cepharanthine, methoxadiantifoline and thalicarpine, whose structural formulas are illustrated herebelow: Structure of ceph_rant ine. METHOX ADIΛ TIFOUNE OCι.3 These Comparative Activities are set forth in Table VII Below CIKMICΛI. S. UCr_.U--ΛN.IKΛlΛMΛ. ACTIVITY Or IJISI.. N/YI.I50QUIN0LINF ALKALOIDS Λ0ΛIN5T PLΛS..0PI...1 fALCIPARUM IN YI1R0 (a): T I-telrandrinc; I f-i_olclrandriπe; IIE.-hernande_ine: BB-berbamiiie; PY-pycnamlne: Pll-p acanlhlne; OB-obamcgine; rΛ-fangchinoline; CY-cyclcanine; CE-cepliHranihinc; iiE-melhoxadianttfoline: Tll-thalicarpine: ■ IC^o of a drug against sensitive strain of P.falclparum Is dcvlded by IC50 for resislanl strain. ■■ S and R represent c loroquine-sensitive and resistant strain of P.falclparum. The results of Table VII illustrate that methoxadiantifoline and those members of the tetrandrine family having the "S" isomeric configuration at the C-1' chiral carbon and having at least one of the R substituent __ comprising CH 3 are actually substantially more effective against the chloroquine resistant malarial strain than against the chloroquine sensitive malarial strain. This extremely surprising result suggests that these compounds actually reverse or inhibit the pumping action of the glycoprotein associated with such multidrug resistant cells. Instead of pumping the toxic drug out of the cell, it actually appears to be pumping a lesser concentration of the toxic drug out of the cell. At present, this is the only reasonable explanation for these surprising results, since the only known significant difference between the multidrug resistant cells and the corresponding drug sensitive cells is the substantially greater percentage of P-glycoprotein associated with the multidrug resistant cell. The foregoing illustrates that the drugs of the present invention provide a treatment for multidrug resistance, whether occurring naturally within a cell or whether occurring through infection in a cell. The present invention is directed primarily to a method for treating such multidrug resistance infection. The drugs of the present invention potentiate the action of primary drugs known to be effective against the multidrug resistance infected disease cells. Of course it is understood that the above is merely a preferred embodiment of the invention and that various changes and alterations can be made without departing from the spirit and the broader aspects thereof.

Claims: -20- The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows. -1- A method for Treating multidrug resistant cancer cells comprising: reversing the P150-170 Kd glycoprotein pumps on multidrug resistant cells such that a greater concentration of toxic drug is conveyed into such multidrug resistant cells than is the case for drug sensitive cells having a substantially lower concentration of said P150-170 Kd glycoproteins. -2- A method for potentiating a primary drug to treat cancer multidrug resistance comprising: exposing multidrug resistant cancer cells to effective concentrations of a compound having the following formula: where R 1 and R., ' are the same or different short chained carbon based ligand; R 2 is CH 3 and R 3 is CH 3 or Hydrogen, and the isomeric configuration at the C-1' chiral carbon location is "S" and at least one of R_ and R 3 comprises CH_. -3- The method of claim 2 is in which said compound comprises tetrandrine. -4- The method of claim 3 in which said compound is used at a dosage level of from about 100 to 300 mg per day. -5- The method of claim 4 wherein the use of said compound is combined with the use of at least one principal drug known to be effective for treating cancer. -6- The method of claim 48 in which said principal drug comprises chloroquine. -7- The method of claim 48 in which the principal drug comprises qinghaosu. -8- The method of claim 5 in which the the principal drug comprises doxorubicin. -9- The method of claim 5 in which the principal drug comprises vinblastine. -10- The method of claim 5 in which the principal drug comprises vincristine. -11- The method of claim 2 in which said compound is used at a dosage level of from about 100 to 300 g per day. -12- The method of claim 2 wherein the use of said compound is combined with the use of at least one principal drug known to be effective for treating cancer. -13- The method of claim 50 in which said principal drug comprises chloroquine. -14- The method of claim 50 in which the principal drug comprises qinghaosu. -15- The method of claim 12 in which the principal drug comprises doxorubicin. -16- The method of claim 12 in which the principal drug comprises vinblastine. -17- The method of claim 12 in which the principal drug comprises vincristine. -18- A method for potentiating a primary drug to treat cell multidrug resistance comprising: exposing multidrug resistant cells to effective concentrations of methoxadiantifoline. -19- The method of claim 18 in which said methoxadiantifoline is used at a dosage level of from about 100 to 300 mg per day. -20- The method of claim 19 wherein the use of said methoxadiantifoline is combined with the use of at least one principal drug known to be effective for treating the disease caused by said multidrug resistant cells. -21- The method of claim 20 in which said principal drug comprises chloroquine. -22- The method of claim 20 in which the principal drug comprises qinghaosu. -23- The method of claim 20 in which the disease treated is cancer and the principal drug comprises doxorubicin. -24- The method of claim 20 in which the disease treated is cancer and the principal drug comprises vinblastine. -25- The method of claim 20 in which the disease treated is cancer and the principal drug comprises vincristine. -26- The method of claim 18 in which said methoxadiantifoline is used at a dosage level of from about 100 to 300 mg per day. -27- The method of claim 18 wherein the use of said methoxadiantifoline is combined with the use of at least one principal drug known to be effective for treating the disease caused by said multidrug resistant cells. -28- The method of claim 27 in which said principal drug comprises chloroquine. -29- The method of claim 27 in which the principal drug comprises qinghaosu. -30- The method of claim 27 in which the disease treated is cancer and the principal drug comprises doxorubicin. -31- The method of claim 27 in which the disease treated is cancer and the principal drug comprises vinblastine. -32- The method of claim 27 in which the disease treated is cancer and the principal drug comprises vincristine. -33- A method for treating cells having multidrug resistance comprising exposing multidrug resistant cells to effective concentrations of tetrandrine in combination with a principal drug known to be effective for treating the disease caused by said multidrug resistant cells where said principal drug is selected from the group consisting of doxorubicin, vinblastine, vincristine, adriamycin, mythra ycin, actinomycin D, colchicine, daunomycin, itoxantrone , VP-16 (podophyllotoxin) . -34- The method of claim 33 in which tetrandrine is used at a dosage level of from about 100 to 300 mg per day. -24- -35- A method for treating nosocomial multidrug resistance infected disease cells comprising: exposing multidrug resistance infected cells to effective concentrations of a compound having the following formula: where χ and R ' are the same or different short chained carbon based ligand; 2 is CH 3 and R 3 is CH 3 or hydrogen, and the isomeric configuration at the c-1* chiral carbon location is "S" and at least one of R, and R 3 comprises CH 3 . -36- The method of claim 35 in which said compound comprises tetrandrine. -37- The method of claim 36 in which said compound is used at a dosage level of from about 100 to 300 mg per day. -38- The method of claim 37 wherein the use of said compound is combined with the use of at least one principal drug known to be effective for treating the disease caused by said multidrug resistant cells. -39- The method of claim 35 wherein the use of said compound is combined with the use of at lest one principal drug known to be effective for treating the disease caused by said multidrug resistant cells. -40- A method for treating nosocomial multidrug resistance infected disease cells comprising: exposing multidrug resistance infected cells to effective concentrations of methoxadiantifoline. -41- The method of claim 40 in which methoxadiantifoline is used at a dosage level of from about 100 to 300 mg per day. -42- The method of claim 41 wherein the use of methoxadiantifoline is combined with the use of at least on principal drug known to be effective for treating the disease caused by said multidrug resistant cells. -43- The method of claim 40 wherein the use of methoxadiantifoline is combined with the use of at least on principal drug known to be effective for treating the disease caused by said multidrug resistant cells. -44- A method for treating multidrug resistant protozoa cells comprising: reversing the P150-170 Kd glycoprotein pumps on multidrug resistant cells such that a greater concentration of toxic drug is conveyed or held into such multidrug resistant cells than is the case for drug sensi¬ tive cells having a substantially lower concentration of said P150-170 Kd glycoproteins. -45- A method for potentiating a primary drug to treat protozoa multidrug resistance comprising: exposing multidrug resistant protozoa cells to effective concentra¬ tions of a compound having the following formula: where R. and R ' are the same or different short chained carbon based ligand; R 2 is CH 3 and R 3 is CH 3 or Hydrogen, and the isomeric configuration at the C-1' chiral carbon location is "S" and at least one of R ≥ and R 3 comprises CH 3 . -46- The method of claim 45 in which said compound comprises tetrandrine. -47- The method of claim 46 in which said compound is used at a dosage level of from about 100 to 300 mg per day. -48- The method of claim 47 wherein the use of said compound is combined with the use of at least one principal drug known to be effective for treating protozoa. -49- The method of claim 45 in which said compound is used at a dosage level of from about 100 to 300 mg per day. -50- The method of claim 45 wherein the use of said compound is combined with the use of at least one principal drug known to be effective for treating protozoa. -51- A method for treating multidrug resistant tuberculosis cells comprising: reversing the P150-170 Kd glycoprotein pumps on multidrug resistant cells such that a greater concentration of toxic drug is conveyed into such multidrug resistant cells than is the case for drug sensitive cells having a substantially lower concentration of said P150-170 Kd glycoproteins. -52- A method for potentiating a primary drug to treat tuberculosis multidrug resistance comprising: exposing multidrug resistant tuberculosis cells to effective concen¬ trations of a compound having the following formula: where R. and R • are the same or different short chained carbon based ligand; R- is CH 3 and R 3 is CH 3 or Hydrogen, and the isomeric configuration at the C-1' chiral carbon location is "S" and at least one of R_ and R 3 comprises CH,. -53- The method of claim 52 in which said compound comprises tetrandrine. -54- The method of claim 53 in which said compound is used at a dosage level of from about 100 to 300 mg per day. -55- The method of claim 54 wherein the use of said compound is combined with the use of at least one principal drug known to be effective for treating tuberculosis. -56- The method of claim 52 in which said compound is used at a dosage level of from about 100 to 300 mg per day. -57- The method of claim 52 wherein the use of said compound is combined with the use of at least one principal drug known to be effective for treating tuberculosis.

Inventors: VAN DYKE KNOX, VAN DYKE, KNOX
Applicants: CBA INT INC, CBA INTERNATIONAL, INC.
Application year: 1992
Main classification: A61K31
IPC codes: A61K31, A61K38, A61P35